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Abstract: Diagnostic- and therapeutic release-aimed nanoparticles require the highest degree 
of biocompatibility. Some physical and chemical characteristics of such nanomaterials are 
often at odds with this requirement. For instance, metals with specific features used as 
contrast agents in magnetic resonance imaging need particular coatings to improve their 
blood solubility and increase their biocompatibility. Other examples come from the 
development of nanocarriers exploiting the different characteristics of two or more 
materials, i.e., the ability to encapsulate a certain drug by one core-material and the targeting 
capability of a different coating surface. Furthermore, all these “human-non-self” 
modifications necessitate proofs of compatibility with the immune system to avoid 
inflammatory reactions and resultant adverse effects for the patient. In the present review we 
discuss the molecular interactions and responses of the immune system to the principal 
nanoparticle surface modifications used in nanomedicine. 
Keywords: immune system; nanomaterials; immunogenicity; immunotoxicity; biodistribution; 
mononuclear phagocytic cells; surface modifications 
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1. Introduction 
The focus of the present review is to describe the main molecular mechanisms of host defense 
towards the principal surface modifications of nanoparticles (NPs) used in medical fields as diagnostics 
or therapeutics. 
A complex variety of organic materials (e.g., polymers, dendrimers, liposomes, proteins and 
carbohydrates), allotropic forms of carbon (e.g., fullerenes, carbon nanotubes) and inorganic nanosized 
particles (e.g., quantum dots, silica, gold or iron core NPs) are currently under investigation for drug 
delivery and imaging purposes [1,2]. 
The nano size of drug delivery vectors is designed to improve solubility, pharmacokinetics and 
biodistribution of small drugs, vaccines or other active molecules, otherwise less effective. Together 
with these advantages, the introduction of such nano-systems may pose biocompatibility concerns that 
go beyond the drug toxicological profile.  
Complex living organisms have perfected their defense mechanisms towards exogenous pathogens 
throughout the course of evolution. The immune system is able to distinguish between self and non-self 
substances. The foreign molecules able to elicit immune responses by binding to specific host receptors 
are called antigens (antibody generators). The immune system ensures a plethora of selective response 
against several non-self molecules retaining immunological memory and preventing injury to host cells 
during responses to microbes. Recognition and subsequent clearance of these alien elements are important 
physiological mechanisms employed by the immune system to maintain the body homeostasis [3]. 
2. A Brief Description of Immune System Main Features 
Different and subsequent lines of defense of increasing specificity are deployed by the immune 
system to eradicate infections by exogenous organisms. Physical barriers, like the skin and mucosa, are 
the first protection of the innate immunity to prevent the entrance of pathogens into the body. If infective 
microorganisms overcome these barriers, another line of innate defense provides an immediate but 
non-specific response. This line of control is carried out by different cellular and biochemical mediators. 
Phagocytic cells, like neutrophils or macrophages, play a major role in wiping out the foreign pathogen 
by encapsulating and destroying it with specific enzymatic reaction cascades. These cells recognize 
unique molecular structures of microbial pathogens, called Pathogen-Associated Molecular Patterns 
(PAMPs), by means of specific pattern-recognition receptors. Well known examples of PAMP-receptors 
are the Toll-like receptors (TLRs) which recognize various microbial molecules including the 
Gram-negative bacteria wall component lipopolysaccharide (LPS), the lipoteichoic acid (present on the 
wall of Gram-positive bacteria) receptor or the receptors for mannose-rich oligosaccharides present on 
the fungi. Innate immune cells are also able to respond to secondary effects like cell damages caused by 
infections. Damage-Associated Molecular Patterns (DAMPs) indicate cell injuries induced by a myriad 
of reasons, including toxins, traumas or decreased nutrient supply. Stress induced proteins, nuclear 
proteins or crystal (i.e., monosodium urate) are recognized by DAMP receptors that initiate immune 
responses. Furthermore, blood proteins can directly interact with the undesired invader and regulate its 
fate. A heterogeneous group of cell derived proteins, named cytokines, synchronize all these immune 
response mechanisms [3]. 
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By means of evolution, most of the vertebrates also possess a further level of protection, the adaptive 
immune response, which can be activated by the innate immunity if pathogens have not been 
successfully eliminated. The adaptive immune system improves its response during an infection and 
“memorizes” pathogen features once it has been eliminated. The immunological memory allows a faster 
and stronger reaction by subsequent exposure to an already recognized element. Indeed, this mechanism 
is the basic principle of vaccination. The adaptive immunity is also called “acquired immunity”, as a 
consequence of its responses against non-self elements “acquired” by experience. The peculiar cells of 
adaptive immunity are the lymphocytes. These antigen-specific cells display receptors that are able to 
recognize an incredible number of exogenous pathogens and to distinguish between very closely related 
molecular structures.  
We can describe two different types of adaptive responses, named humoral and cell-mediated 
immunity, often working contemporaneously and in conjunction with the innate system. The humoral 
immunity is mediated by proteins called antibodies. This family of proteins is secreted by B lymphocytes 
(or B cells) once differentiated into antibody-secreting plasmacells. The process of recognition of 
pathogens by B lymphocytes is also mediated by antibody receptors expressed on the cell surface that 
trigger an intracellular signaling leading to cell differentiation upon foreign molecule binding. In 
contrast, cell-mediated reactions begin with a coordinated interaction between a different type of 
lymphocytes, the T lymphocytes (or T cells), and Antigen Presenting Cells (APCs). T cells are not 
capable of producing antibodies and have a restricted specificity for antigens [4]. They recognize only 
foreign peptides bound to host molecules, the major histocompatibility complex (MHC) exposed on the 
presenting cells. One of the main tasks of adaptive cell-mediated immunity is to destroy microbes that 
survive and proliferate inside the cells, like viruses. Functionally different subpopulations of 
T lymphocytes play a role in the various kinds of infections. All these subsets are grouped in two main 
families, known as T helper (THLs) and cytotoxic T cells (CTLs). The antigenic stimulation induces 
T helper cells to secrete cytokines, which in turn foster proliferation and differentiation of T cells, 
B cells, macrophages and other leukocytes. Cytotoxic T lymphocytes are equipped with specific set of 
reactive proteins capable to kill cells that expose foreign antigens on their surface. A third group of 
lymphocytes is represented by natural killer (NK) cells, which are principally involved in innate 
response towards microbes and pathogens [5]. Lymphocytes and APCs circulate through the body and 
home to the target sites of antigen exposure. Lymphoid organs, like spleen, liver or lymph nodes 
represent the anatomical districts where these cells increase the possibility of antigen presentation and 
start an immune response [6]. 
All the immune cells travel within the body in a strictly regulated manner. Differentiated cells from 
all the tissues provide signals to drive the immune cell travelling, mainly releasing chemokines 
(chemoattractant cytokines) [7]. This very special type of polypeptides has a conserved structure which 
is maintained in the evolution, highlighting the importance of their role in cell migration. The tissue 
modifications happening during inflammatory processes are intended for leukocytes recruitment from 
the circulation to the injured tissue with the purpose of destroying pathogens. Indeed, the majority of the 
cell movements implicated in the physiological tissue rearrangements and pathological conditions rely 
on chemokine driven signaling [8]. 
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As well as microbes, most of the engineered nanomaterials that enter the body are recognized as 
non-self by the immune system, which efficiently detects and tries to eliminate them through the 
described mechanisms [9]. This biological event makes the immune system a crucial obstacle to deal 
with, in order to apply nanotechnology to biomedicine. 
3. Nanoparticle Interaction with Blood Components and Uptake by Phagocytic Cells 
Critical physical and chemical features of NPs regulate the interaction with the immune system. 
Surface electrostatic charges of engineered nanomaterials are fundamental to define immune 
responses [10]. Positive-charged surfaces on the particles are often more cytotoxic than anionic and 
neutral ones. Cationic NPs bind more efficiently than anionic charged or neutral molecules to the 
negatively charged plasma membrane of target cells, which expose the negative charges of the 
phospholipidic groups. Once NPs have entered the cell, NP surface positive charge slows down the 
acidification of endosomes (responsible for the transport pathway from the plasma membrane to the 
lysosome), thereby delaying the endosome–lysosome transition. Moreover, they can cause more 
pronounced disruption of plasma-membrane integrity, stronger mitochondrial, lysosomal damage, and 
increased number of autophagosomes [11,12]. Positively charged elements introduced into cells may 
also form complexes with the negatively charged nucleic acids raising genotoxicity concerns. However, 
a net positive surface charge helps the binding to plasma membranes. This physical effect can be 
beneficial for drug delivery particles. 
The different uptake preferences of phagocytic and nonphagocytic cells for cationic and anionic NPs 
are important for the efficacy and selectivity of NPs. In general, neutral particles show lower interaction 
with the cell membrane than charged (cationic or anionic) nanoparticles of the same size, due to the 
lower number of electrostatic interactions between NP-surface and charged cell membranes. Designing 
optimal coatings for drug delivery carriers requires a precise characterization of these physical interactions.  
Drug or gene delivery nanocarriers for systemic injection in the bloodstream come across a biological 
milieu composed of cells, proteins and solutes [13]. Injected NPs almost instantaneously adsorb and bind 
different proteins, whose affinity kinetics depends on the nano-material surface, charge and size. The 
protein layer created on the particle surface is called “corona” and it influences particle biodistribution 
and circulation time. Proteins that increase the clearance of exogenous particles by specialized 
mononuclear phagocytes are called opsonins. Blood released antibodies, for example, principally work 
as opsonins enhancing phagocytosis. Molecules that activate the complement system (see below) are 
also considered opsonins. Their binding to NPs injected in the bloodstream leads to the attachment of 
macrophages followed by cell internalization. This type of internalization is highly regulated by cells 
surface receptors and their capability of binding to the particular protein corona attached to the particle. 
A detailed characterization of NP-specific opsonization process will help to design nanoparticle with 
future clinical relevance. 
The protein corona hiding the surface of NPs determines the effective size and the final 
beneficial/dangerous effects of the material. Besides enhancing particle recognition by the host immune 
cells, protein adsorption/opsonization increases the hydrodynamic diameter (HD) which contributes to 
modify NP accumulation and tissue distribution. Generally HD is greatly larger than the NP diameter 
measured after their synthesis. The HD of particles injected in the bloodstream is inversely related to 
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glomerular filtration rate in the kidney, ultimately regulating the blood half-life of the solutes [14]. 
Molecules with an HD < 5 nm achieve a rapid equilibrium with the extravascular extracellular space 
(EES), whereas larger particles have prolonged circulatory times due to slow transport across the 
endothelium [15,16]. 
The opsonization process of NPs may involve the blood proteins of the complement system, which 
refers to about 30 small blood molecules (serum proteins and cell membrane receptors) synthesized by 
the liver [17]. This system helps and “complements” the action of innate and adaptive immunity and has 
an important role in leukocytes chemotaxis and bacteria lysis. Upon stimulation, specific proteases 
cleave downstream peptides to release cytokines, thus initiating an amplifying the proteolytic cascade to 
further cleavages. The end-result is a massive amplification of the response and subsequent activation of 
APCs, T and B cells. Complement can be activated through three different biochemical ways: the 
classical, the alternative and the lectin pathway. The several types of NPs can differently activate the 
complement system through one specific pathway or a combination of them [18]. The specificity of the 
activated pathway by NPs depends on their surface properties, such as the conformation of a particular 
polymer coating [19–21]. 
The activation of complement protein cascades can be responsible for some adverse effects  
(i.e., hypersensitivity and anaphylaxis). To avoid such events, nano-formulations intended for systemic 
administration of drug carriers are usually designed to prevent the complement activation. 
As previously mentioned, NP physicochemical properties regulate their recognition and uptake by 
phagocytic cells. In the past decades it was believed that phagocytosis was restricted to large matter 
(>1 μm). However, like other cells, macrophages can also use different routes of internalization like 
endocytosis and macropinocytosis to uptake nanosized particles. It has been observed that nanoparticles 
>500 nm are primarily and more efficiently internalized via macropinocytosis or phagocytosis 
mechanism than smaller ones with the same composition and surface properties [18,22]. NPs with 
dissimilar morphologies interact with macrophages in a different way. As expected, the longest 
dimensions exhibit the strongest attachment with macrophages membranes. Nonetheless, virus-sized 
particles (20–200 nm) are efficiently taken up by macrophages or APCs, but mainly via clathrin-coated 
mediated endocytosis [23]. 
Once internalized within immune cells, NPs can activate cytoplasmic multiprotein complexes called 
inflammasomes, which are involved in the initiation of inflammatory responses [24]. These complexes 
induce the proteolysis of inflammatory cytokine precursors and the following release of the bioactive 
mediators. Endo/lysosome compartment damage and the release of hydrolytic enzymes, such as 
Cathepsin B seem to play a major role in NP-induced inflammasome-dependent interleukin-1β (IL-1β) 
release by macrophages and DCs [25]. 
Unfortunately, the information regarding the interaction of nanomaterials with the immune system is 
still limited and fragmentary. Many results have been obtained in vitro using mouse or human 
immortalized cell lines. The differences between mouse and human immune systems rise up some 
concern on the potential clinic reliability. A second issue to be considered is the constitutive release of 
inflammatory factors or growing hormones by immune cell lines, otherwise suppressed by primary cells 
or temporary expressed after external stimuli. Furthermore, the several synthesis processes to produce 
the same nanomaterials may introduce discrepancies in the resulting in vivo outcomes. 
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In this review we report and comment on what is known in literature on the immunological 
characterization of the principal inorganic and organic materials usually exploited in NP coating for 
biomedical applications. To better focus on the surface material-related immune events, we will not 
describe and discuss NP functionalization with peptides or other biological moieties intended for 
specific cell targeting. 
4. NP Surface Coatings 
The employment of synthetic polymers to coat NPs increases their stability and solubility with 
advantageous effects on cytotoxicity or inflammatory responses following administration [26]. Active 
molecules can be encapsulated (adsorbed or bound) into the coated carriers to protected them from 
metabolizing enzymes. Specific NP surfaces can confer protection to non-target tissues from a possible 
unspecific toxic action of the drug payloads leading to side effects of the pharmaceutics. On the other 
hand, they protect the drug from premature release or degradation in the biological environment of the 
body, preserving their efficacy. 
As well as delivery carriers, different type of shells cover NPs aimed at imaging and more in general 
at diagnosis. For instance, contrast agents for Magnetic Resonance Imaging (MRI), like 
super-paramagnetic iron oxide (SPIO) NPs or paramagnetic gadolinium-labeled NPs are often coated 
with polymers to increase their solubility and biocompatibility [27]. 
Conversely, the coating can be chosen to produce immune-stimulant reactions, as demonstrated by 
the application of NPs as adjuvant in vaccines production, which is becoming a field of fast development 
in pharmaceutical industry [28]. In this case, reactive surfaces stimulate specific immune cells in order to 
increase the response to antigens. 
Therefore, NP surface features and materials must be considered as key factors that may significantly 
contribute to adverse immune reactions and toxicity in current healthcare practice. In the following 
paragraphs, representative observations will describe the type of interaction that the mainly used 
NP-coating materials have with the immune system and their proved or potential effects. 
5. Synthetic Polymeric Coatings 
5.1. Polyethylene Glycol (PEG) 
Hydrophobic surfaces generally tend to exclude water molecules causing aggregation and 
precipitation of unstable colloids with limited biological applications. NP surface can be modified by 
using highly hydrophilic polymers, such as poly(ethyleneglycol) (PEG) [26]. PEG is a polyether chain 
able to absorb water and generate hydrogen bonds that allow solubilization in polar solvents and the 
stabilization of the colloid either in acidic or basic pH environments. As we mentioned before, charged 
nanoparticles bind more proteins than particles with neutral surfaces. Surface neutralization by coating 
with PEG is one of the best approaches to protect nanoparticle surface from protein binding. 
Two different approaches are mainly used to obtain PEG-coated nanoparticles: PEG adsorption or the 
covalent attachment of the polyether chain on the surface, usually called PEGylation [29]. PEG 
adsorption is the simpler approach, but it is barely useful in the case of NPs released in a biological 
environment. Since this polymer is highly water-soluble, the coating might be immediately dissolved in 
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salty fluids. PEGylation represents the best way to stably attach the polyether chain on the surface for 
biomedical applications. A third way to obtain PEGylation is using amphiphilic di-block copolymers to 
form NPs. In this case, self-assembling micellar structures can be produced and loaded with the  
desired cargo [30].  
As consequence of PEG coating NP internalization by phagocytes is reduced prolonging their 
circulation time when released in the blood [13]. However, PEG covering of some materials like 
liposomes does not protect from complement activation. The presence of specific chemical groups on 
the polymer shell may modulate this effect. For instance, linkers like hydroxy and thiol-groups do not 
activate the complement cascade, while methoxy groups potently trigger the cleavage reaction [21]. 
Different structural conformation and chemical group charges may determine the complement binding 
with associated immune responses. 
Most of the data present in literature describing antigenic responses to NPs surface coatings are 
provided by experiments using PEGylated liposomes. Repeated systemic administrations of these 
nano-systems induce an antibody-dependent rapid clearance of the second dose from the circulation [13]. 
This phenomenon is called accelerated blood clearance (ABC). The ABC effect seems to be 
accompanied by the accumulation of both PEGylated and uncoated liposomes in the liver and spleen 
immune resident cells. Phagocytic cells depletion attenuates this process, suggesting that macrophages 
are involved in NPs accelerated clearance. The rate of the ABC phenomenon depends on many factors, 
like the dose, the interval between the administered doses, the NP size, the surface charge, the liposomal 
composition and the PEG density. 
Nowadays, PEG coatings show many advantages to produce “stealth” NPs able to avoid a major 
activation of immune system. This is proved by its abundant use as sole coating or in combination with 
other polymers. Nevertheless, clinical studies employing PEGylated NPs for long time are not available 
to assure its complete immune-safety. 
5.2. PLGA 
Poly(lactic-co-glycolic acid) (PLGA) is one of the most successfully developed polymers for 
therapeutic devices, owing to its biodegradability and biocompatibility [31]. PLGA is synthesized by 
co-polymerization of two different monomers, the cyclic dimers of glycolic acid and lactic acid. 
Depending on the ratio of lactide to glycolide used for the polymerization, different forms of PLGA can 
be obtained. Although the homopolymers of lactic acid (polylactide) and glycolic acid (polyglycolide) 
show poor solubility, PLGA can be dissolved by a wide range of common solvents. 
Under normal physiological conditions, PLGA undergoes hydrolysis in the body and produces its 
original monomers. Since they are by-products of various metabolic pathways in the body, there is minimal 
systemic toxicity associated with the use of PLGA for drug delivery or other biomedical applications.  
PLGA is described in the literature as a promising carrier adjuvant for nasal subunit vaccines. Glycol 
chitosan coated PLGA (GC-PLGA) NPs were found to elicit relatively stronger immune response as 
compared to chitosan coated PLGA (C-PLGA) and PLGA NPs after nasal administration [32]. 
GC-PLGA NPs showed a better mucoadhesivity, with consequently prolonged nasal residence time. 
Furthermore, GC-PLGA NPs resulted in a more efficient antigen uptake and transport across the nasal 
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mucosa and into the circulatory system. The coating of NPs with chitosan and glycol chitosan did not 
affect the integrity and release profile of the antigen. 
Surface-modified PLGA microspheres (cationic PLGA microspheres) were also described as potent 
nasal delivery systems for vaccines where mucosal, humoral and cellular responses after bacterial and 
viral pathogens invasion are required [33]. 
It is worth noting that PLGA particulate vaccine adjuvants enhance LPS-induced NALP3 
inflammasome and Caspase 1 activation leading to increased IL-1β secretion [34,35]. This observation 
emphasizes the complexity of immune responses to NPs even for those usually considered non-toxic and 
biodegradable. It can be hypothesized that the presence of PLGA coating helped to increase the 
efficiency of the adjuvant delivery without a direct involvement in the immune response. The 
enhancement of an inflammatory pathway born after particle internalization, that is, the inflammasome 
activation, would suggest the hydrolyzation of the PLGA coating within the cell. 
The advantage of using PLGA as a good and biodegradable protection for the desired cargo also 
seems a good choice for the immune-compatibility of the polymer, based on the absence of detrimental 
effects in the available literature. 
5.3. Dendrimers 
Dendrimers molecules are highly-branched symmetric structures which are synthesized in a 
layer-by-layer fashion expressed in “generations” (G) around a core unit. This structure has repeated 
dendrons with a single chemical linking group, called focal point. Their synthesis results in high level of 
control over size, branching points and surface functionality. Several kinds of inorganic nanoparticles, 
coated with dendrimers are reported in literature for drug and gene delivery [36–38] or imaging [39]. 
Many detailed results are available on dendrimer toxicity either in vitro or in vivo [40]. However, 
information on the immune system reactions to dendrimer is still less well explored. Glycodendrimers 
containing various surface modifications have been designed as anti-infective ligands with anti-viral or 
antimicrobial effects. As examples, a polysulfonate G4 polyamidoamine (PAMAM) dendrimer show the 
ability to block HIV-1 and HIV-2 activity in vitro [41]. Although the mechanism of infection prevention 
is mainly related to structural entrapment of the virus by the branched structure, dendrimer-related 
antimicrobial activity may also involve immune-modulation. For instance, N-acetyl-glucosamine-coated 
G1 PAMAMs administered in mice bearing subcutaneous melanoma model, decrease tumor growth and 
increase mice survival. These results were accompanied by an increase of CD69+ cells in the spleen and 
the tumor tissue, associated to the up-regulation of IL-1h, IFN-g, TNF-a and IL-2 [42]. Another 
indication of such phenomenon is provided by the over-expression of pro-inflammatory chemokines and 
cytokines, namely MIP-1a, MIP-1h, IL-8, TNF-a, IL-1h and IL-6 induced in human dendritic cells and 
macrophages by glucosamine-modified G3.5 PAMAMs [43]. 
Many different dendrimer compositions can be synthesized and each one should be studied using 
primary immune cells and animal models in order to understand and eventually classify the different 
features of immune responses. It is clear that cationic dendrimers can damage cell membranes and this 
event can activate innate inflammatory reactions mediated by DAMP receptors, which could recognize 
cell components escaping from their intracellular location. 
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6. Natural Polymeric Coatings 
Among the natural polymers, chitosan, sodium alginate and dextran are frequently used to cover NPs. 
However, the information on immune effects is often restricted to the bulk material or to some 
specific application. 
6.1. Chitosan 
Chitosan (Chi) is a linear polysaccharide, extensively diffused in biomedical applications for its 
excellent properties including rapid blood clotting, biodegradability, non-toxicity, high charge density, 
gelling and mucoadhesivity. These features give to chitosan an immense potential for various 
pharmaceutical applications, such as the coating or entrapment of biochemicals, drugs and antigenic 
molecules. An example is represented by chitosan microspheres, which have been studied as promising 
carrier systems for mucosal vaccination (especially oral and nasal) to induce enhanced immune 
responses [32]. 
This natural polymer can be employed both for inorganic and organic nano-structures. Literature 
reports chitosan coatings of different metallic NPs [44,45]. Chi has been shown to enhance the function 
of immune cells, such as neutrophils and macrophages stimulating the production of cytokines and 
growth factors [46–49]. However, Chi is also controversially employed as a “fat binder” to reduce body 
weight. The mechanism of interaction between chitosan and fat is not well understood and has not been 
proved clinically. No indications of specific immune responses have been clearly shown following oral 
administration of chitosan tablets or pills. On the other hand, due to its adjuvant properties that increase 
inflammatory responses, caution should be used before choosing this polysaccharide as NP coating. 
6.2. Sodium Alginate 
Sodium alginate is a hydrophilic, water soluble and biocompatible polysaccharide obtained by marine 
brown algae. Alginate consists of α-L-guluronate and β-D-mannuronate, arranged in a block structure as 
homopolymer (polyguluronate or polymannuronate) or heteropolymer (a mixed sequence of these residues).  
It is often employed as a coating for magnetic [50] and polymeric NPs [51,52]; alginate oligomers 
obtained by enzymatic digestion of alginate polymer are able to induce the secretion of high levels of 
inflammatory cytokine and chemokines, like MCP-1, RANTES in vitro and in vivo [53,54]. 
Combinations of alginate and poly-lactide-co-glycolide acid (PLGA) are developed for vaccination 
purposes. Immunization studies in Balb/c mice by intradermal route demonstrated that incorporation of 
alginate elicited humoral and cellular immune responses [33,55]. 
Enhancement of non-specific immune responses demonstrated in vivo suggests the employment of 
alginate as coating for NPs aimed at immune stimulation. Either for vaccine adjuvant properties or for 
diagnostic purposes to reveal deficient innate immune reaction, this brown algae-derived anionic 
polysaccharide may represent a useful tool in biomedicine applications of NPs. 
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6.3. Dextran 
Dextran is a complex, branched polysaccharide composed of many glucose molecules. It is widely 
used in medicine as an anti-thrombotic (anti-platelet action) and blood viscosity reducer. Larger 
dextrans, which do not cross the vessels, are potent osmotic agents, and thus volume expanders in 
hypovolemia.  
Dextran is also diffused for the realization of metallic NP coatings to protect core oxidation. Dextran 
coatings can be obtained by adsorption [56], chemical functionalization [27,57] or directly during 
nanoparticle formation [58]. 
Even if extensively employed for NP shells, a few studies investigated the effects of such surfaces on 
the immune system. Potential immune stimulatory effects on mouse splenocytes have been achieved 
using drug loaded chitosan-carboxymethyl dextran NPs (CDNP) [59]. Unfortunately, it is difficult to 
understand the specific contribution or role of the dextran in those kinds of immune responses.  
The complex of two or more polymers can create surfaces with very different characteristics and 
immune reactions. 
Immune effects resulting from the release of free dextran molecules (not in nano-complexes) are not 
useful to establish its immunogenicity as NP coating. Many inflammatory reactions depend on the 
molecular weight of the chosen polysaccharide, its branching structure and the administered dose. 
6.4. Starch 
Starch is a different natural polymer produced by plants such as corn, potato, rise and cassava. It is 
composed of two biomolecules, namely amylose and amylopectin. Amylose is a linear polymer of 
glucose units mainly linked with alpha-1,4-bonds. Amylopectin, an extremely high molecular weight 
polymer, has the same backbone structure of amylose, but with many alpha-1,6-linked branch points. 
This polymer is highly biocompatible and biodegradable, with different physicochemical properties 
according to the type of starch source [60]. 
Due to all these features, starch is widely used in many different biomedical applications ranging 
from skin topical release [61] to degradable drug microsphere carrier [62]. Starch based coating have 
also been employed for gold [63] or iron-core magnetic NPs [64,65]. 
Although commonly used, the literature regarding immune system interaction with starch coated NPs 
is poor. It is unclear whether stereotyped immune reactions can be associated with the starch surface. 
Due to its wide presence in food and its biodegradability, starch is considered a “safe” material. It is 
expected, however, that potential allergic reaction will be experienced only in a restricted number of 
sensitive human recipients, as well as for the other materials. 
7. Inorganic NP Coatings 
Inorganic covering of NPs is frequently used to produce NPs for applications involving specific 
characteristics of the coating material. Due to the lower solubility of their coating properties, they are 
less applied than the organic polymers for NP delivery in biomedicine. Data on the immune reactions 
towards inorganic NPs are frequently associated to secondary effects following cell internalization of the 
particles. NP size and charge play a major role in toxicity, intracellular localization and membrane 
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damages that lead to DAMPs release by injured cells and inflammasome activation in the phagocytes. 
Immune secondary events limit the possibility to find common responses to a certain coating material 
and restrict the observations to the particles employed in a specific study. 
7.1. Silica 
Silicon dioxide NPs (SiO2 NPs) are exploited in a wide range of applications and in particular for 
biomedical research. Dense or porous silica inorganic coatings are also used to shell different NP 
cores [66]. SiO2 NPs have demonstrated low toxicity in vitro suggesting a positive role of silica shell 
around different core materials, including CdSe/Zn QDs [67–69]. As described earlier, phagocytes such 
as macrophages and monocytes react more efficiently to micro-size particles than to nano-size particles. 
Moreover, increased cell damage has been shown for silica micro-particles than for nano-particles [18]. 
An interesting work by Fruijtier-Polloth and colleagues demonstrated that interaction between 
amorphous silica nanoparticles and endothelial cells promotes the upregulation of endothelial adhesion 
molecules expression. This effect enhances the adhesion of monocytes to endothelial cells, a typical 
early event of inflammatory processes [70]. Moreover, many immunotoxic effects are due to the 
interference with signaling pathways involved in activation of the immune response or the release of 
pro-inflammatory cytokines or chemokines [71]. 
Morishige and colleagues demonstrated that chemical modification of silica NP surfaces can decrease 
or suppress inflammasome activation and IL-1β release in THP-1 human monocyte/macrophage cell 
line [25]. However, it is important to note that these inflammatory outcomes have been proved using 
1 μm particles. Nano-scale silica particles, ranging from 30 to 300 nm, did not induce IL-1β release. 
These results suggest that inflammatory responses of silica nanoparticles could depend on the 
combination of several features, including size and surface functionalization. 
It is worth mentioning that many indications come from cancer models where the immune system is 
not in a physiological condition [72]. Further experiments specifically planned would help to better 
decipher the silica coated NPs impact on the immune system. 
7.2. Gold 
Gold coatings are generally used for the preparation of bimetallic particles, containing a magnetic 
core as platform for surface functionalization. Some strategies reported in literature describe different 
core-shell NPs covered with this metal [73,74]. Gold-coated nanoparticles (Au-shelled NPs) have been 
particularly designed for biomedicine, especially for drug delivery [75] and cancer applied hyperthermia 
treatments [76,77].  
There are controversial studies concerning the toxicological effects of engineering gold nanoparticles. 
A study by Hashimoto et al. compared the exposure of cultured macrophages RAW264.7 to AuNPs 
with AgNPs. Although an inflammatory response was observed for both the Au- and Ag-NPs, the 
harmful cytotoxic effects of AuNPs were smaller than those of the Ag-NPs [78]. However, as described 
for other kinds of nanomaterials, the interaction between cells and Au nanoparticles could be mediated 
also by unspecific adsorption of serum proteins onto the gold surface [79]. 
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7.3. Titanium Dioxide (TiO2) 
Titanium dioxide (TiO2) is another coating for inorganic nanoparticles, exploited to increase their 
cytocompatibility. It was reported that a titanium oxide shell on Zn-based nanoparticles reduces zinc 
ions release in human lung epithelial cell line [80]. More recent studies demonstrated that core/shell iron 
oxide/titanium oxide nanoparticles can be used as doxorubicin vector for cancer cells [81]. There are 
contentious data about TiO2 toxicity. TiO2 particles are considered to be inert and unable to pass 
undamaged skin. For this reason, they are commonly used for cosmetics or sunscreens preparations as an 
efficient filter of UV light [82]. In contrast, other studies reported cell toxicity and genotoxicity [83–85]. 
The discrepancy may be due to different TiO2 particle compositions, different cellular origin, or 
variation in TiO2 sensitivity between the organisms. TiO2 acts as a modulator of neutrophil 
degranulation, typically associated with inflammatory process. Actually, it enhances cell surface 
expression of some granule markers, the secretion of some proteins in the supernatants and 
metalloproteinases activity in human neutrophils [86]. 
8. Discussion and Conclusions 
Nanoparticles designed for biomedical applications in vivo inevitably encounter the human Immune 
System. Many aspects of nanoparticle-induced modulation of immune responses have been investigated 
and comprehensive literature on the subject has been published [9,18]. In this review we have revised the 
available literature focusing on the immune aspects specifically due to different surface coatings of NPs, 
independently of their size, shape and core composition (summary in Table 1). We also excluded the 
protein functionalization of the surfaces, which could inevitably induce a ligand-receptor driven 
targeting of the particle or stimulate specific immune pathways on purpose. 
It is important to have an overview on this subject; however, it is difficult to draw conclusions or even 
compare the several ways to shell NPs. The choice of the NP coatings firstly relies on the chemical 
feature of the employed materials. For example, not all the polymers can be covalently attached or 
adsorbed onto different metal cores. The use of surfactants may be helpful for solubility improvement, 
but can completely change the immune response. Experimental approaches that clearly avoid 
false-positive or false-negative immunotoxicological results of nano-systems are not simple. Secondly, 
the NPs end goal may limit the application of a specific NP coating. For instance, NPs aimed at clinical 
applications could require high temperature sterilization processes. These particles cannot be coated 
with polymers that liquefy at high temperatures. In this case the surface that the immune cells will face 
would not be the original polymer but either a modified polymer or the core material. 
Precise design of NP organic or inorganic coatings to avoid or specifically interact (e.g., coadjuvants) 
with the Immune System could be done only if the binding sites were clearly known. Polymers differ by 
chemical groups that present unique composition and structure. The different metallic or metal oxides 
NPs show diverse reactivity on their surfaces depending on their atomic and crystal structure. So, several 
features should be considered, like sizes of antibody binding sites vs. their potential interaction site on 
the NP surface. Moreover, the biological conditions and opsonization by diverse molecules in vivo may 
dramatically alter all these parameters. 
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Table 1. Immune response summary of surface coatings. 
Surface 
coatings 
Origin Immune response Cell mediator Applications References 
Polyethylene 
glycol (PEG) 
Synthetic Complement activation Phagocytic cells 
Biomedical 
applications 
[13,21,26,29,30] 
Poly(lactic-co 
glycolic acid) 
(PLGA) 
Synthetic Antigen-mediated 
NALP3 
inflammasome 
and Caspase 1 
activation 
Drug delivery, 
vaccine adjuvant 
[31–35] 
Dendrimers Synthetic 
Innate DAMP 
receptors-mediated 
Dendritic cells 
and 
macrophages 
Anti-infective 
ligands 
[36–43] 
Chitosan Natural 
Innate immune 
response 
Neutrophils and 
macrophages 
Coating of drugs, 
vaccine adjuvant 
[32,44–49] 
Sodium 
alginate 
Natural 
Humoral and cellular 
response 
Neutrophils and 
macrophages 
Coating for 
magnetic and 
polymeric NPs, 
vaccines 
[33,50,53–55] 
Dextran Natural Not well defined Not well defined 
Anti-platelet 
action, metallic 
NP coatings 
[27,56–59] 
Starch Natural 
Low immune and 
allergic responses 
Not well defined 
Skin topical 
release, gold or 
iron-core 
magnetic NPs 
 [60–65] 
Silica Inorganic 
Inflammasome 
activation 
DAMPs release 
Endothelial 
cells, 
monocytes 
Biomedical 
research 
[18,25,66–72] 
Gold Inorganic 
Serum protein 
mediated-inflammatory 
response 
Not well defined 
Magnetic 
core,cancer 
applied 
hyperthermia 
[73–79] 
Titanium 
dioxide 
(TiO2) 
Inorganic 
Secretion of proteins, 
metalloproteinases 
activation 
Neutrophils 
Vector for cancer 
cells, cosmetics 
[81–85] 
In view of all this complexity, special attention must also be paid to in vitro and in vivo models for 
immunology studies. Although currently used in the laboratory, these models provide limited 
information regarding a potential immune response in human subjects. Immune cell lines are often used 
as in vitro models. These cell types are proliferating clones that differ from primary immune cells which 
are extracted from a donor in a physiological state. Primary cells are usually cultured and tested within a 
couple of weeks. Although the window of time to perform experiments on each donor is shorter than 
using a cell line, this represents the best in vitro model. Primary white blood cells represent a reliable 
model to assess the cellular and molecular immune responses following cellular activation pathways by 
the NPs. The possible release of inflammatory cytokines in the supernatant can also be carefully 
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quantified in culture. The weak point of all the in vitro systems is the isolated and artificial environment 
of the culture. Different sera, media and mutated cell lines of the same origin have produced 
contradictory results. It is difficult to predict with reasonable certainty what will happen once NPs are 
administered in vivo. Most of these experiments, however, are necessary to exclude some responses and 
orientate the researches towards specific outcomes. If high doses of a certain NP do not induce 
pico-molar doses of inflammatory cytokines in vitro it will be unlikely that the same particle will induce 
cytokine release in relevant amounts in vivo. On the other hand, a different reaction cannot be excluded 
in a living organism as a consequence of orchestrated reactions of different cell types. 
In vivo experimental models are definitely required to understand systemic immune reactions. The 
elected model for immunology is the mouse. Selected strains of mice are commercially available and 
permit the investigation in fast reproducing and easy-to-handle mammals. Their immune system is not 
exactly like the human one, but the cell types and the main features are very similar. Moreover, modern 
biotechnology provides genetically modified animals missing genes involved in specific immune 
reaction. Genetically modified mice for immunity genes provide the most straightforward evidence for 
potential immune system activation induced by NPs. Model mice with a specific disease offer the 
opportunity to study the specific immunological events induced by the nano-carrier potentially 
employed as drug delivery system for the same disease. The latter consideration assumes that specific 
disease states could present altered immune responses limiting the information collected from 
experiments of NP release in healthy mice. 
In vivo models are mandatory when the targets of delivery are protected organs like the Central 
Nervous System (CNS). The optimal way to deliver NPs to the CNS would be through the blood 
circulation. Nonetheless, the presence of the Blood-Brain-Barrier (BBB) increases the level of difficulty 
for delivering drug carriers. The BBB acts as a rigorously regulated gate for the flow of ions, 
macromolecules, and nutrients between blood and brain tissue, as well as potential hazards. It combines 
physical and metabolic barriers to maintain the homeostasis of the CNS [87]. However, reaching the 
CNS through blood flow is very difficult, although very attractive due to the reduced invasiveness of 
intravenous administration compared to intracerebroventricular (ICV) or intraparenchymal (IP) injections. 
The preparation of NPs for applications in the CNS implies a peculiar design of the surface and 
specific particle properties. Polymeric NPs or coating with surfactants like polysorbates or PEG have 
been traditionally used as a strategy to cross the BBB [88–90]. These approaches have been applied with 
comprehensive chemical design of the nano-vectors and many observations of neural cell responses. 
Fewer details are available on the immune responses happening in the CNS, once NPs have been 
introduced in the neural parenchyma. 
The CNS resident immune system is represented by microglial cells [91]. These cells are able to sense 
pathological tissue alteration and perform immunological functions, besides many other emerging 
functions in maintaining the homeostasis of the healthy CNS. 
As already pointed out, PEGylation is one of the most used materials to reduce protein opsonization 
on the NP surface, limiting the immune system response. It has been observed that uncoated lipid NPs, 
which accumulate in the brain parenchyma after intravenous injection, cause considerable microglia 
activation. PEG coating of those lipid NPs with PEG strongly reduce microglial activation [92]. 
We already mentioned the PEG or PLGA coating of magnetic NPs designed as contrast agents for 
MRI imaging in the CNS. A novel approach is represented by magnetic core coated with lipid 
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modified-PAMAM dendrimers [93]. No indications on immune reactions towards this type of NPs have 
been presented yet. However, very recent results on G4 amine-PAMAMs and lipid-modified 
amine-PAMAMs emphasize the importance of the dendrimer modification of the regulation of 
inflammatory cytokine and chemokine receptors on microglia surface [94]. On the other hand, PAMAM 
dendrimers alone have already been employed for CNS delivery in vivo demonstrating helpful features 
for neuro-inflammatory disease models [95]. 
As described in this review, nanomaterials applied to biomedicine can be designed to avoid or target 
the immune system. The advent of engineered NPs has highlighted the importance of immunosafety 
tests to understand the behavior of immune cells in response to these formulations. Unfortunately, 
nano-sized systems often interfere with the assays usually used by immunologists. Generally, 
experimental results can be affected by chemical or biological contamination and by optical interference 
related to the material density. Traditional in vitro tests do not usually contemplate the use of NPs and 
their possible optical and catalytic interference with the employed reagents and cellular model. 
Moreover, traces of impurities (solvents, carry-over molecules) and/or endotoxin within a 
nano-formulation can also induce an inflammatory response, causing cellular- and immunotoxicity [96]. 
The development of new nanomaterial-aimed techniques and assays will help to validate the already 
existing results and to unify the results obtained from different methods. 
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